Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2 1

Status

Withdrawn 1Unknown 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

NET 2Gastrointestinal 2Endocrine 2

Conditions

Neuroendocrine Tumors 7Pheochromocytoma 2Paraganglioma 2Gastro-enteropancreatic neuroendocrine tumor 2Vipoma 1Thymus Neoplasms 1Neoplasms, Unknown Primary 1Neoplasms 1Meningioma 1Insulinoma 1Gastrinoma 1Carcinoma, Merkel Cell 1Carcinoid Tumor 1

Interventions

lutetium Lu 177 dotatate 5copper dotatate CU-64 3Magnetic Resonance Spectroscopy 3lanreotide 2gallium Ga 68 dotatate 2Nivolumab 2Lutetium-177 2Lutetium 2Ga(III)-DOTATOC 2Carboplatin 2177Lu-octreotide, DOTA(0)-Tyr(3)- 2zimberelimab 1regorafenib 1pembrolizumab 1pasireotide 1irinotecan sucrosofate 1folfirinox 1cabozantinib 1abemaciclib 1X-Rays 1Temozolomide 1Somatostatin 1Resveratrol 1Radiosurgery 1Octreotide 1Ipilimumab 1Granulocyte Colony-Stimulating Factor 1Fluorodeoxyglucose F18 1Filgrastim 1Etoposide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Gastro-enteropancreatic neuroendocrine tumor × 177Lu-octreotide, DOTA(0)-Tyr(3)- × Clear all
NCT05359146 2024-04-19

Beta plus

University Hospital, Basel, Switzerland

Phase EARLY_PHASE1 Unknown
16 enrolled
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor

NCT04915144 2023-02-21

177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs

British Columbia Cancer Agency

Phase 2 Withdrawn
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Carcinoid Tumor, Vipoma, Insulinoma, Gastrinoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡